This arrangement aims to further broaden access of these medicines beyond the current geographies to benefit many more patients, more efficiently, by significantly extending the reach of healthcare professionals through an expanded field force.
This brings together the manufacturing and development synergies of NIL with the sales and distribution strengths of
Barring unforeseen circumstances, this has the potential to drive value for shareholders of NIL.
This strategic business decision is leading to the separation of approximately 400 employees of NIL due to role redundancies. We understand the implications of this difficult decision on those impacted and their loved ones and we are extending a severance package along with outplacement services.
Both organisations will remain fully committed to patients and will continue to focus on providing uninterrupted supply of medicines.
About Novartis' philosophy of collaborating with stakeholders in the healthcare ecosystem, Sanjay says, 'We are committed to working with organizations that resonate with our purpose of improving and extending people's lives. To that end, we collaborate with entities such as the government, patient organizations, start-ups, industry associations, healthcare providers, pharmaceutical companies amongst others, who are working towards reducing barriers in the journey of a patient ranging from awareness, diagnosis, access and adherence.'
Novartis has a large footprint in
Over the last five years, Novartis has spent over
About Novartis in
Since 1947, Novartis has had a significant footprint in
About Novartis
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis medicines reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com
Contact:
Novartis India Media
E: vaishali.iyer@novartis.com
E: aditi.roy@novartis.com
(C) 2022 Electronic News Publishing, source